Author Login

• Editorial
• Open Access
• Ralf Hofheiewnz

The United States of America (USA) licensed trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), about 25 years ago for the treatment of patients with metastatic HER2-positive breast cancer.

• Review Article
• Open Access
• Lauera-Maria Krawbbe

Bladder cancer accounts for almost 200,000 fatalities globally in 2018 and is diagnosed in roughly 550000 new cases annually [1]. Bladder cancer is one of the most costly cancers to treat because it requires frequent follow-up, invasive procedures like cystoscopy, repetitive procedures like transurethral resection of bladder tumors and intravesical instillation therapy in non-muscle invasive stages.

• Case Report
• Open Access
• Brieuc Sauetois

Numerous proteins, including the poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) enzymes, which are essential for repairing single-strand DNA breaks, and the homologous recombination repair (HRR)-related proteins BRCA1, BRCA2, and RAD51, facilitate DNA repair.

• Editorial
• Open Access
• Kostaeds A.Papavassesiliou

Tumor microenvironment (TME) emphasis has lately replaced tumor-centricity as the primary focus of cancer research and treatment [1]. Malignant cells, immune cells, stromal cells, blood and lymph vessels, neuron fibers, extracellular matrix (ECM), and other acellular components make up the TME, which is a dynamic ecosystem.

• Research Article
• Open Access
• ÖzgüSl Düzgün

One of the most prevalent pelvic tumors in women is uterine carcinoma (UC). In females, the lifetime risk for UC is approximately 4% [1]. Women between the ages of 60 and 70 are typically affected. After receiving surgery, chemotherapy, radiation therapy, and hormone therapy, UC has a favorable prognosis; additionally, UC accounts for just 2% of cancerrelated deaths.